Salik Choudhary, MD
Critical Care Medicine · Belleville, ILNPI 1386986578
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,541 and has fallen 56.3% since, to $674 in 2025.
Across 179 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$969
- Sanofi$619
- AstraZeneca$547
- Regeneron Healthcare Solutions, Inc.$320
- Intuitive Surgical$289
- Insmed, Inc.$253
- plus $1K from 20 others
What the payments were for
- Travel & lodging$2897%
- Food & beverage$3,80491%
- Education$892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 49 | $969 |
| Sanofi | 21 | $619 |
| AstraZeneca | 19 | $547 |
| Regeneron Healthcare Solutions, Inc. | 10 | $320 |
| Intuitive Surgical | 2 | $289 |
| Insmed, Inc. | 14 | $253 |
| Boehringer Ingelheim | 12 | $250 |
| Merck | 5 | $200 |
| Electromed, Inc. | 20 | $168 |
| Johnson & Johnson(2 entities) | 4 | $99 |
| Grifols USA, LLC | 4 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Harmony Biosciences LLC | 1 | $39 |
| Philips North America LLC | 2 | $37 |
| Resmed Corp | 1 | $26 |
| Mylan Specialty L.p. | 2 | $26 |
| Pinnacle Biologics, Inc | 1 | $25 |
| Ambu Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Optinose US, Inc. | 1 | $21 |
| Shionogi Inc | 1 | $18 |
| Circassia Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$283
- TEZSPIRE$230
- NUCALA$223
- WINREVAIR$123
- DUPIXENT$122
How this compares
$4,182 in reported general payments places this provider in the 85th percentile of 281 critical care medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 398 | $299,466 |
| TezspireTezepelumab-Ekko | 29 | $136,916 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 146 | $103,320 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 152 | $86,445 |
| NucalaMepolizumab | 17 | $63,121 |
| Spiriva RespimatTiotropium Bromide | 69 | $37,733 |
| Advair HfaFluticasone Propion/Salmeterol | 71 | $26,276 |
| SymbicortBudesonide/Formoterol Fumarate | 78 | $22,440 |
| Spiriva HandihalerTiotropium Bromide | 28 | $18,427 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 60 | $14,791 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $14,534 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $11,376 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 361 | $10,091 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $10,062 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $9,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta, Breo Ellipta | $969 | $470,227618 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $547 | $262,676253 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $250 | $62,329110 claims |
| MerckDulera | $200 | $5,05315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 critical care medicine providers in Illinois.
Other critical care medicine in Belleville
- Danielle HughesBelleville$5K
- Zachary YoungBelleville$3K
- Brian ReichardtO Fallon$892K
- Michael CutticaChicago$402K
- Daniel DillingMaywood$208K
- Israel RubinsteinChicago$107K
- John RickelmanQuincy$90K
- Abbas Al-QamariChicago$40K
- Husam NayefPalos Park$24K
- Nureain MirzaOak Lawn$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.